Clinical Research Papers:
Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival
Metrics: PDF 1035 views | HTML 1517 views | ?
Qianqian Zhu1,*, Na Li1,*, Xiaoyan Zeng2, Qunying Han1, Fang Li1, Cuiling Yang1, Yi Lv3,4, Zhihua Zhou1, Zhengwen Liu1,4
1Department of Infectious Diseases, First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, 710061 Shaanxi, China
2Department of Laboratory Medicine, First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, 710061 Shaanxi, China
3Department of Hepatobiliary Surgery, First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, 710061 Shaanxi, China
4Institute of Advanced Surgical Technology and Engineering, Xi’an Jiaotong University, Xi’an, 710061 Shaanxi, China
*These authors have contributed equally to this work
Zhengwen Liu, e-mail: email@example.com
Keywords: hepatocellular carcinoma, feature, treatment, survival, diagnosis
Received: November 04, 2014 Accepted: December 11, 2014 Published: February 24, 2015
Hepatocellular carcinoma (HCC) is among the most common and lethal cancers worldwide, especially in China.
We retrospectively analyzed data from patients who were diagnosed and treated HCC between 2002 and 2011 in a large hospital in northwest China and compared the data between periods 2002–2006 (P1) and 2007–2011 (P2).
2045 patients were included in analysis. The HCC stages at diagnosis according to the Barcelona clinic liver cancer staging system had no significant change. Treatment options of liver transplantation, transcatheter arterial chemoembolization and other therapy decreased while percutaneous local ablation and supportive care increased from P1 to P2. Options of surgical resection and systematic therapy had no significant change. Patient survival rates at 1, 3 and 5 years significantly improved from P1 to P2. The treatments with increasing option trend had a higher magnitude of survival increase and vise versa.
Over the last 10 years, the patient survival had a significant increase which was mainly a result of the optimal therapeutic selections according to disease stages in this center. However, the proportion of patients diagnosed at early stages of HCC remained low and did not increase, a result calling for implementing surveillance system for at risk patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.